Skip to main content
. 2018 Jun 24;10(7):812. doi: 10.3390/nu10070812

Table 12.

Accounting for the AMS-AUC values for garlic supplements having active alliinase.

Product and Meal RRF (%) AUC (ng-h/L) Rfalliin 1 % of Alliin to AMS 2 % Contribution to AMS-AUC
Alliin 3 Allyl Polysulfides 4 Alliin + Allyl Polysulfides G/SAC 5
RFG/SAC 6 0.49 2.0 0.49 2.0 0.49 0.49 0.49 2.0 0.49 2.0
N3 (LP) 111 1247 7.9 109 98 <2 98 2
C3 (HP) 109 733 6.8 95 93 <2 93 7
E5 (LP) 104 407 7.2 100 79 13 92 8
N2 (LP) 93 294 5.7 79 76 14 90 10
E1 (LP) 91 802 5.9 82 98 <2 98 2
N1 (LP) 80 400 4.8 67 86 7 93 7
E4 (LP) 71 826 4.3 60 91 5 96 4
E2 (LP) 69 782 5.6 78 97 2 99 1
E1 (HP) 57 496 3.6 50 96 <2 96 4
C1 (LP) 54 267 3.4 48 94 <2 94 6
E3 (LP) 36 720 2.3 2.0 32 28 84 13 97 87 3 13
E2 (HP) 33 324 2.4 2.0 31 28 92 5 97 89 3 11
C2 (LP) 26 290 1.3 0.3 18 4 75 6 81 23 19 77
E3 (HP) 22 432 1.2 0.9 16 13 73 22 95 79 5 21

1 The RFalliin value needed to obtain the observed AUC = (AUC − AUCallyl polysulfides − AUCG/SAC)/μmol alliin. AUCallyl polysulfides = RFallyl polysulfides (7.2) × μmol allyl polysulfides; AUCG/SAC = RFG/SAC (0.49 or 2.0) × μmol G/SAC; amounts of alliin, allyl polysulfides, and G/SAC are in Table 4. 2 Percent of the alliin in the product that has been metabolized to AMS through garlic’s alliinase activity = 100 × RFalliin divided by the RF value for alliin (7.2) when alliinase is not inhibited. The small amount of alliin metabolized to AMS independent of alliinase (RFalliin < 0.67) has not been included. 3 Percent of breath AMS-AUC that comes from alliin = RFalliin × μmolalliin consumed × 100/AUC. 4 Percent of breath AMS-AUC that comes from allyl polysulfides = RFallyl polysulfides × μmolallyl polysulfides consumed × 100/AUC. 5 Percent of breath AMS-AUC that comes from G/SAC = RFG/SAC (0.49 or 2.0) × μmolG/SAC consumed × 100/AUC. 6 Response factors for G/SAC. The value of 0.49 is based on consumption of pure SAC. The value of 2.0 represents the estimated enhanced in-garlic response factor when alliinase is mostly, but probably not completely, inhibited in vivo; it is applied here only when the allicin bioavailability is less than 40%.